Switching to dolutegravir plus rilpivirine versus maintaining current antiretroviral therapy regimen in virologically suppressed people with HIV-1 and the Lys103Asn (K103N) mutation: 48-week results from a randomised, open-label pilot clinical trial
Titel:
Switching to dolutegravir plus rilpivirine versus maintaining current antiretroviral therapy regimen in virologically suppressed people with HIV-1 and the Lys103Asn (K103N) mutation: 48-week results from a randomised, open-label pilot clinical trial
Auteur:
Moyle, Graeme Assoumou, Lambert de Castro, Nathalie Post, Frank A Curran, Adrian Rusconi, Stefano De Wit, Stephane Stephan, Christoph Raffi, François Johnson, Margaret Masia, Mar Vera, Jaime Jones, Bryn Grove, Richard Fletcher, Carl Duffy, Annie Morris, Kellie Pozniak, Anton